Safety and efficacy of oral nemonoxacin versus levofloxacin in treatment of community-acquired pneumonia: A phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled, non-inferiority trial

Background/Purpose: Nemonoxacin is a novel nonfluorinated quinolone with excellent in vitro activity against most pathogens in community-acquired pneumonia (CAP), especially Gram-positive isolates. The purpose of this study was to assess the efficacy and safety of nemonoxacin compared with levofloxa...

Full description

Bibliographic Details
Main Authors: Jinyi Yuan, Biwen Mo, Zhuang Ma, Yuan Lv, Shih-Lung Cheng, Yanping Yang, Zhaohui Tong, Renguang Wu, Shenghua Sun, Zhaolong Cao, Jufang Wu, Demei Zhu, Liwen Chang, Yingyuan Zhang, Li Zhao, Xiongbiao Wang, Xuefen Wang, Dexi Wang, Xiangyang Li, Yiqiang Peng, Yongjie Liang, Hua Liu, Zuke Xiao, Xiaoju Lv, Shiman Wu, Yuanrong Dai, Yijiang Huang, Zhenghong Hu, Chen Qiu, Xi Li, Suiyang Zhang, Wenpu Li, Shuang Liu, Yi Shi, Chang Xiong, Jiulong Kuang, Qingyu Xiu, Shehuai Cui, Jianguo Li, Qichang Lin, Wenxiang Huang, Yixin Wan, Qimanguli, Ce Shen, Yi Xiao, Xiaoju Wu, Yin Ching Chuang, Wann Cherng Perng, Shih-Ming Tsao, Jeng-Yuan Hsu, Chin-Chou Wang, Jen-Hsien Wang, Pen-Fang Yeh, His-Hsun Lin, P.H. Kuo, Ming-Shian Lin, Wei-Juin Su
Format: Article
Language:English
Published: Elsevier 2019-02-01
Series:Journal of Microbiology, Immunology and Infection
Online Access:http://www.sciencedirect.com/science/article/pii/S1684118217301512